Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec:21:100276.
doi: 10.1016/j.ensci.2020.100276. Epub 2020 Sep 20.

Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report

Affiliations
Case Reports

Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report

Peter Novak. eNeurologicalSci. 2020 Dec.

Abstract

Coronavirus disease (COVID-19) is a novel highly contagious infectious disease caused by the coronavirus SARS-CoV2. The virus affects the human respiratory and other systems, and presents mostly as acute respiratory syndrome with fever, fatigue, dry cough, myalgia and dyspnea. The clinical manifestations vary from no symptoms to multiple organ failure. Majority of patients fully recover. Several postinfectious presumably autoimmune complications of COVID-19 affecting the brain or peripheral large nerve fibers have been reported. This report describes a post COVID-19 patient who developed chronic fatigue, orthostatic dizziness and brain fog consistent with orthostatic hypoperfusion syndrome (OCHOS), a form of orthostatic intolerance, and painful small fiber neuropathy (SFN). Initially, the patient was diagnosed with. OCHOS (detected by the tilt test with transcranial Doppler monitoring) and SFN (confirmed by skin biopsy), and both OCHOS/SFN were attributed to Post Treatment Lyme Disease Syndrome of presumed autoimmune etiology. Patient recovered on symptomatic therapy. COVID-19 triggered exacerbation of OCHOS/SFN responded to immunotherapy with intravenous immunoglobulins. This case suggests that post COVID-19 syndrome may present as an autoimmune OCHOS/SFN and that early immunotherapy may be effective. Further studies are necessary to confirm the link between OCHOS/SFN and COVID-19 disease as well as to confirm the benefit of immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Dr. Novak is advisor – independent Contractor for Dysimmune Diseases Foundation. Dr. Novak received speaker's honoraria from KabaFusion and Lundbeck, he is a member of the Scientific Advisory Board of Endonovo Therapeutics. Dr. Novak received royalties from Oxford University Press.

References

    1. Zhang X., Tan Y., Ling Y. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020 Jul;583(7816):437–440. doi: 10.1038/s41586-020-2355-0. Epub. - DOI - PubMed
    1. Koralnik I.J., Tyler K.L. COVID-19: a global threat to the nervous system. Ann. Neurol. 2020 Jul;88(1):1–11. doi: 10.1002/ana.25807. Epub. - DOI - PMC - PubMed
    1. Dalakas M.C. Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol. Neuroimmunol. Neuroinflam. 2020;7 - PMC - PubMed
    1. Novak P. Orthostatic cerebral hypoperfusion syndrome. Front. Aging Neurosci. 2016;8:22. - PMC - PubMed
    1. Hovaguimian A., Gibbons C.H. Diagnosis and treatment of pain in small-fiber neuropathy. Curr. Pain Headache Rep. 2011;15:193–200. - PMC - PubMed

Publication types